FDA approves first 4-in-1 flu vaccine

Federal health officials have approved the first vaccine that protects against four strains of the common flu, offering one additional layer of protection against the influenza virus that affects millions each year.

The FluMist Quadrivalent vaccine from AstraZeneca's unit protects against two strains of influenza A and two strains of influenza B. The approved the spray-based vaccine for people ages 2 to 49.

Previously all vaccines contained two strains of influenza A and one strain of influenza B, chosen annually by medical experts based on their potential to spread the virus. Having an extra strain of influenza B increases the likelihood that the vaccine will protect against illness, the FDA said in a statement.

Similar to the previously approved FluMist, the new vaccine is a nasal spray that delivers weakened strains of the virus.

"Illness caused by Influenza B virus affects children, particularly young and school-aged, more than any other population," said Dr. Karen Midthun, M.D., director of the FDA's biologics center.

The severity of illness and death due to flu varies widely from season to season. Between 1976 and 2007, flu-related deaths have ranged from an estimated low of about 3,000 to a high of about 49,000 people, according to the FDA.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

NIH experts describe influenza vaccines of the future

Nov 17, 2010

In a review article appearing in the New England Journal of Medicine, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine research under way to ...

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments